Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of SGLT-2 Inhibition on SNS Activity
NCT03912909Phase 4Unknown
- Sponsor
- Royal Perth Hospital
- Start
- Aug 2018
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of empagliflozin in metabolic syndrome, type 2 diabetes mellitus (T2DM), obesity, sponsored by Royal Perth Hospital. Status: unknown.
02
Drugs
empagliflozin
03
Conditions
metabolic syndrometype 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT03912909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03912909.